Dermira’s DRM04 Soars in Two Phase 3 Trials

Dermira’s topical anticholinergic candidate DRM04 shined in two Phase 3 trials for the treatment of primary axillary hyperhidrosis, or excessive sweating.

The candidate demonstrated statistically significant results compared to a placebo in both trials, meeting both primary endpoints and both secondary endpoints compared to the placebo. Additionally, it met one of its co-primary endpoints and both secondary endpoints.

The company plans on submitting its NDA for DRM04 during the latter half of 2017.